第十八届东方心脏病学会议（The 18th Oriental Congress of Cardiology，OCC 2024）与世界心脏病学大会（World Congress of Cardiology，WCC 2024）将于2024年6月27日至30日在上海国际会议中心盛大开幕。
作为心血管领域备受瞩目的盛会，这两大会议汇聚了全球顶尖的专家学者，共同探讨心血管疾病的最新研究成果、治疗技术和未来发展趋势。特别是在结构性心脏病这一重要分支上，与会者将深入交流最新的临床数据和研究成果，共同推动该领域的研究和治疗向前迈进。
The 18th Oriental Congress of Cardiology (OCC 2024) and the World Congress of Cardiology (WCC 2024) will be grandly held at the Shanghai International Convention Center from June 27 to 30, 2024.
As highly anticipated events in the field of cardiology, these two conferences will gather top experts and scholars from around the world to discuss the latest research findings, treatment techniques, and future development trends in cardiovascular diseases. Specifically, in the crucial subfield of structural heart disease, participants will engage in in-depth exchanges on the latest clinical data and research outcomes, jointly advancing research and treatment in this area.
论坛时间：2024年6月29日 星期六
论坛地点：上海国际会议中心3CD
论坛坛主：新加坡国家心脏中心Jack Tan教授；浙江大学医学院附属第二医院王建安院士
Forum Date:Saturday,June 29 2024 ；
Forum Venue: 3CD，Shanghai International Conference Centre
Forum Chairs:
Professor Jack Tan, National Heart Centre Singapore;
Professor Wang Jian'an, The Second Affiliated Hospital, School of Medicine, Zhejiang University.
Jack Tan教授
王建安院士
心脏瓣膜病
Heart valve disease
在全球范围内，心脏瓣膜病的治疗需求日益增加，这不仅是因为人口老龄化带来的自然增长，更是因为医疗技术的进步使得越来越多的患者能够从中受益。
南非的Liesl Zuhkle教授将以其深厚的专业知识和丰富的临床经验，为我们详细阐述心脏瓣膜病的全球需求，以及当前结构性心脏病领域在影像学和治疗技术上的实际考虑与创新。
The treatment demand for heart valve diseases is increasing globally, not only due to the natural growth brought by the aging population, but also because medical technology advances enable more and more patients to benefit from them.
Professor Liesl Zuhkle from South Africa will elaborate on the global demand for heart valve diseases, as well as the practical considerations and innovations in imaging and treatment technologies in the current field of structural heart diseases, with her profound professional knowledge and rich clinical experience.
二尖瓣修复技术
Mitral valve repair technology
谈及结构性心脏病的治疗时，二尖瓣修复技术无疑是其中一颗璀璨的明星。二尖瓣作为心脏中至关重要的瓣膜之一，其健康状态直接关系到心脏的正常运行。一旦二尖瓣受损或功能失调，就可能导致严重的心脏疾病。
在这一重要领域，泰国胸外科医师协会的主席 Taweesak Chotivatanapong教授将以其丰富的临床经验和专业知识，与我们分享关于二尖瓣修复的宝贵经验，引领我们探索更多关于二尖瓣治疗的新知识。
When discussing the treatment of structural heart diseases, mitral valve repair technology undoubtedly stands out as a brilliant star. The mitral valve, one of the crucial valves in the heart, directly relates to the normal functioning of the heart. Any impairment or malfunction of the mitral valve can lead to severe heart diseases.
In this significant field, Professor Taweesak Chotivatanapong from Thailand will share his valuable experience in mitral valve repair, drawing from his rich clinical expertise and professional knowledge. He will guide us to explore more new knowledge about mitral valve treatment.
中国力量，勇于创新
Chinese Strength, Courageous in Innovation!
在结构性心脏病的治疗领域，技术的创新是推动治疗进展的关键力量。复旦大学附属中山医院的潘文志教授将深入探讨单纯主动脉瓣反流经股动脉TAVR（经导管主动脉瓣置换术）在中国的创新实践，这一突破性的技术不仅充分展现了中国在结构性心脏病治疗领域的尖端实力，而且为患者提供了更为安全、高效的治疗方案。
与此同时，上海交通大学医学院附属第一人民医院的陆方林教授将聚焦于中国三尖瓣反流介入治疗器械的创新成果。三尖瓣反流作为一种常见的结构性心脏病，其治疗技术的创新同样至关重要。陆教授将分享中国在这一领域取得的显著进展，这些创新不仅为患者提供了更多样化、个性化的治疗选择，更是中国医疗技术不断发展、突破自我的重要标志。
In the field of structural heart disease treatment, technological innovation is the key force driving progress. Professor Pan Wenzhi from Zhongshan Hospital, Fudan University, will delve into the innovative practice of Transcatheter Aortic Valve Replacement (TAVR) via femoral artery for pure aortic regurgitation in China. This breakthrough technology not only fully demonstrates China's cutting-edge strength in the field of structural heart disease treatment, but also provides patients with a safer and more efficient treatment plan.
At the same time, Professor Lu Fanglin from the First People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine will focus on the innovative achievements in interventional treatment devices for tricuspid regurgitation in China. As a common structural heart disease, the innovation of treatment techniques for tricuspid regurgitation is equally crucial. Professor Lu will share China's significant progress in this field, which not only provides patients with more diverse and personalized treatment options, but also marks the continuous development and self-breakthrough of Chinese medical technology.
我们热切期盼着即将召开的WCC结构性心脏病论坛。此次论坛的盛大召开，无疑预示着结构性心脏病治疗领域即将迎来崭新的突破与无限的机遇。全球顶尖的专家学者将共同探索结构性心脏病治疗的前沿技术，分享宝贵的临床经验，为患者提供更加精准、高效的治疗方案。让我们携手共进，为结构性心脏病的治疗领域注入新的活力，为患者带来福音！
We eagerly anticipate the upcoming WCC-Structural Heart Disease Forum. The grand opening of this forum undoubtedly heralds new breakthroughs and boundless opportunities in the field of structural heart disease treatment. Top global experts and scholars will jointly explore cutting-edge technologies in structural heart disease treatment, share valuable clinical experiences, and provide patients with more precise and effective treatment plans. Let's work together to inject new vitality into the field of structural heart disease treatment and bring blessings to patients!
欢迎注册
会议时间：2024年6月27-30日
会议地点：上海国际会议中心
注册官网：www.occmd.org
Conference Dates：June 27-30, 2024
Conference Venue：Shanghai International Convention Center
Registration Website：www.occmd.org
审核：王建安 钱菊英 陆国平 徐亚伟
医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。